Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 09 Aug 2023
At underground launch control centers at a nuclear missile base in Montana, where a startlingly high number of men and women have reported cancer diagnoses, the Air Force found unsafe levels of a likely carcinogen.
Read Full NewsPsychotropics are associated with increased BMI, and users with a high BMI genetic risk score and an unhealthy lifestyle have triple the risk for CVD, new research shows.
Tafasitamab and lenalidomide are likely to be approved with R-CHOP for frontline DLBCL, but with bispecific antibodies on the horizon, the role of the combination is uncertain.
In a phase 3 trial of patients with dedifferentiated liposarcoma, the CDK4/6 inhibitor extended progression-free survival more than sixfold.
A phase 3 trial evaluates a PARP inhibitor or placebo plus an androgen pathway inhibitor to treat men with advanced prostate cancer associated with genetic changes.
In the first phase 3 trial of teclistamab monotherapy, the bispecific antibody was associated with better PFS and OS than standard regimens in relapsed or refractory multiple myeloma.
A phase 3 trial evaluates the safety and efficacy of an investigational bispecific antibody with chemotherapy compared to standard treatment in advanced squamous NSCLC.
In an interim analysis of a randomized phase 2 trial, asandeutertinib improved intracranial response and intracranial PFS vs osimertinib in patients with EGFR-mutated NSCLC with brain metastases.
1.
HER3 Antibody Drug Conjugate Shows Promise in NSCLC
2.
Pancreatic cancer patients who were prescribed lorazepam for anxiety had poorer survival rates.
3.
New tumor therapy approach reduces costs and side effects while increasing accessibility
4.
Cancer Vaccines' Emergence; More Focus on Side Effects; A Nudge for Exercise.
5.
Pollution exposure may affect lung cancer in women who have never smoked
1.
The Mysterious World of Petechiae: Exploring Causes and Treatments
2.
IGSF8: A Rising Star in Cancer Immunotherapy - Harnessing the Innate Immune System
3.
Beyond the Blood: Expanding CAR T-Cell Therapy to Solid Tumors- A New Era of Precision Oncology
4.
Sound Waves and Self-Destruction: A Promising Nanotech Weapon in the Fight Against Cancer
5.
Unlocking the Mystery of Hemoglobin C Trait: A Closer Look at a Rare Blood Disorder
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias
2.
Navigating the Complexities of Ph Negative ALL - Part XIV
3.
CDK4/6 Inhibitors in Extending Overall Survival in HR+/HER2- aBC Patients in Clinical Trial and Real World
4.
Managing CNS diseases at the point of diagnosis in ALK + NSCLC
5.
The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge